PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Fulgent Genetics, Inc. (FLGT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS3596641098
CUSIP359664109
SectorHealthcare
IndustryDiagnostics & Research

Highlights

Market Cap$608.78M
EPS-$5.63
PE Ratio9.30
PEG Ratio1.32
Revenue (TTM)$289.21M
Gross Profit (TTM)$366.90M
EBITDA (TTM)-$46.55M
Year Range$19.88 - $44.09
Target Price$26.67
Short %3.67%
Short Ratio2.23

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Fulgent Genetics, Inc.

Popular comparisons: FLGT vs. XLV, FLGT vs. CPRX, FLGT vs. SMG, FLGT vs. SWPPX

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Fulgent Genetics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%-10.00%0.00%10.00%20.00%30.00%NovemberDecember2024FebruaryMarchApril
-16.20%
21.11%
FLGT (Fulgent Genetics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Fulgent Genetics, Inc. had a return of -28.61% year-to-date (YTD) and -31.22% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-28.61%6.30%
1 month-5.36%-3.13%
6 months-18.45%19.37%
1 year-31.22%22.56%
5 years (annualized)23.00%11.65%
10 years (annualized)N/A10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-14.94%-8.26%-3.81%
2023-18.38%-10.47%15.20%4.82%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of FLGT is 20, indicating that it is in the bottom 20% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of FLGT is 2020
Fulgent Genetics, Inc.(FLGT)
The Sharpe Ratio Rank of FLGT is 1414Sharpe Ratio Rank
The Sortino Ratio Rank of FLGT is 1414Sortino Ratio Rank
The Omega Ratio Rank of FLGT is 1515Omega Ratio Rank
The Calmar Ratio Rank of FLGT is 2929Calmar Ratio Rank
The Martin Ratio Rank of FLGT is 2626Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Fulgent Genetics, Inc. (FLGT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


FLGT
Sharpe ratio
The chart of Sharpe ratio for FLGT, currently valued at -0.74, compared to the broader market-2.00-1.000.001.002.003.00-0.74
Sortino ratio
The chart of Sortino ratio for FLGT, currently valued at -1.06, compared to the broader market-4.00-2.000.002.004.006.00-1.06
Omega ratio
The chart of Omega ratio for FLGT, currently valued at 0.87, compared to the broader market0.501.001.500.87
Calmar ratio
The chart of Calmar ratio for FLGT, currently valued at -0.35, compared to the broader market0.001.002.003.004.005.00-0.35
Martin ratio
The chart of Martin ratio for FLGT, currently valued at -1.02, compared to the broader market0.0010.0020.0030.00-1.02
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.92, compared to the broader market-2.00-1.000.001.002.003.001.92
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.78, compared to the broader market-4.00-2.000.002.004.006.002.78
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.47, compared to the broader market0.001.002.003.004.005.001.47
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.64, compared to the broader market0.0010.0020.0030.007.64

Sharpe Ratio

The current Fulgent Genetics, Inc. Sharpe ratio is -0.74. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.74
1.92
FLGT (Fulgent Genetics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Fulgent Genetics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-88.77%
-3.50%
FLGT (Fulgent Genetics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Fulgent Genetics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Fulgent Genetics, Inc. was 89.07%, occurring on Apr 17, 2024. The portfolio has not yet recovered.

The current Fulgent Genetics, Inc. drawdown is 88.77%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-89.07%Feb 10, 2021801Apr 17, 2024
-77.98%Jan 17, 2017216Nov 21, 2017488Nov 8, 2019704
-65.82%Feb 19, 202019Mar 16, 202083Jul 14, 2020102
-45.97%Aug 21, 202012Sep 8, 202066Dec 10, 202078
-32.49%Nov 11, 20195Nov 15, 201955Feb 6, 202060

Volatility

Volatility Chart

The current Fulgent Genetics, Inc. volatility is 7.04%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%NovemberDecember2024FebruaryMarchApril
7.04%
3.58%
FLGT (Fulgent Genetics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Fulgent Genetics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items